] . (2019). Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet HIV, 6(5), e297-e306. presented at the 2019 05. doi:10.1016/S2352-3018(19)30053-0
. (2012). The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol, 188(10), 5166-76. presented at the 2012 May 15. doi:10.4049/jimmunol.1102756